The ongoing phase Ib/IIa trial has assessed efficacy, safety and duration of response to SM101 in 36 ITP patients.
The company will report the data under the title ”Interim Results from a Phase Ib/IIa Clinical Trial with the Soluble Fc-gamma-IIB Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia”.
SM101 is a recombinant, soluble, non-glycosylated version of the Fc-gamma-receptor IIB that binds to autoantibody/autoantigen complexes and blocks the activation of Fc receptors on the surface of immune cells.